Immuneering Corporation (IMRX)
NASDAQ · Healthcare
Immuneering Corporation EBITDA 2020–2023
Immuneering Corporation annual/quarterly ebitda history and growth rate from 2023 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Immuneering Corporation ebitda for the quarter ending September 30, 2023 was -13.8 M, a 5.55% increase year-over-year.
- Immuneering Corporation ebitda for the twelve months ending September 30, 2023 was -55.0 M.
- Immuneering Corporation annual ebitda for 2023 was -58.1 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Immuneering Corporation EBITDA — FAQ
Immuneering Corporation (IMRX) ebitda over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IMRX's ebitda history?
The chart and table above show Immuneering Corporation's ebitda by year and by quarter, including the growth rate.